Moderna reports third quarter 2023 financial results and provides business updates

Third quarter 2023 revenues of $1.8 billion; company expects 2023 revenues of at least $6 billion spikevax u.s. market share to date increased to 45% from 36% in 2022 company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025 company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowance company's late-stage pipeline has six phase 3 programs company expects to break even in 2026 through product launches and disciplined investment cambridge, ma / accesswire / november 2, 2023 / moderna, inc. (nasdaq:mrna) today reported financial results and provided business updates for the third quarter of 2023. "through this quarter, we demonstrated our ability to increase share in the u.s. market, and we now expect this year's vaccination rate to be similar to last fall," said stÉphane bancel, chief executive officer of moderna.
MRNA Ratings Summary
MRNA Quant Ranking